BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
Go back to BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 65.44 -1.09 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.53 | 52 Week High | $108.96 | |||
| Open | $65.24 | 52 Week Low | $62.12 | |||
| Day High | $66.26 | P/E | N/A | |||
| Day Low | $64.01 | EPS | $-1.27 | |||
| Volume | 461,202 | |||||
